Nectero Medical, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Nectero Medical, Inc. - overview
Established
2017
Location
Tempe, AZ, US
Primary Industry
Biotechnology
About
Founded in 2017 and based in Arizona, US, Nectero Medical, Inc. operates as a biotechnology company developing a minimally invasive treatment for small- to mid-sized AAAs. In April 2024, Nectero Medical Inc. raised USD 96 million in Series D funding led by Norwest Venture Partners, Boston Scientific Corporation, BioStar Capital, Cadence Healthcare Ventures, and Aphelion Capital.
The Series D funding values Nectero Medical Inc. at USD 139. 81 million post-money. As of 2024, the company is led by its president and CEO, Jack Springer.
Nectero Medical is a clinical-stage biotech platform that develops novel therapies for patients with infrarenal abdominal aortic aneurysms (AAAs). The company provides an investigational treatment called Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST®) System, a single-use, endovascular system that targets abdominal aortic aneurysms (AAA), specifically small- to mid-sized ones (maximum diameter 3. 5–5 cm). The company plans to use the funds raised in April 2024 to conduct Phase II and III trials and submit a new drug application to the U.
S. Food and Drug Administration.
Current Investors
Boston Scientific Ventures, Norwest Venture Partners, BioStar Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.necteromedical.com
Company Stage
Series D
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.